Sanofi ADS (SNY) DIvidends Date & History

Key Takeaways

• Sanofi (SNY) pays a dividend of approximately $1.76 per share, translating to a dividend yield near 4%.
• The company distributes its dividend once per year, a schedule common among European-listed pharmaceutical firms.
• Sanofi's payout ratio sits around 37% of earnings and roughly 30% of free cash flow, indicating a conservative and well-covered dividend.
• The dividend has grown at an average annual rate of roughly 5% over the past five years.
• With a stable, defensive healthcare business, Sanofi is positioned as a candidate for income-focused and long-term dividend investors.

Dividend Overview

Sanofi, a France-based global pharmaceutical company, distributes its dividend annually rather than quarterly. Its most recent distribution of $1.76 per share was paid in June 2026 following a May 4, 2026 ex-dividend date. Based on this annual payment, SNY offers a dividend yield of roughly 4%, which places it above the average for large-cap healthcare names.

Sanofi is best described as a dividend growth stock with an attractive current yield. While its once-a-year payment schedule differs from the quarterly cadence that many U.S. investors expect, the underlying dividend has been dependable and gradually increasing. The company's policy reflects a commitment to returning capital to shareholders while retaining enough earnings to fund research and development across its pharmaceuticals and vaccines portfolio.

Dividend History and Growth

Sanofi has a long record of returning cash to shareholders. In recent years, the annual dividend has climbed steadily: the payout rose from approximately $1.37 per share in 2023 to about $1.48 in 2024 and $1.60 in 2025, before reaching roughly $1.76 in 2026. This represents year-over-year increases of roughly 7% to 10% in most recent periods.

Over a longer five-year horizon, Sanofi's dividend has compounded at an average annual rate of about 5%. The company has maintained or raised its dividend consistently for more than two decades, reflecting management's confidence in the durability of its cash flows. That said, investors should note that the dividend is declared in euros and converted to U.S. dollars for American Depositary Receipt (ADR) holders, meaning currency fluctuations can cause the dollar-denominated payout to vary from year to year.

Dividend Sustainability and Payout Ratio

Sanofi's dividend appears well supported by its earnings and cash generation. The company pays out roughly 37% of its earnings and around 30% of its free cash flow in dividends, leaving a substantial cushion to fund operations, reinvest in its pipeline, and absorb temporary setbacks. A payout ratio in this range is generally considered conservative and sustainable for a large pharmaceutical company.

The healthcare sector's defensive characteristics also support dividend reliability. Demand for medicines and vaccines tends to remain stable across economic cycles, which helps Sanofi generate predictable cash flows. While the company, like all drugmakers, faces patent expirations and pipeline risk, its diversified portfolio across specialty care, vaccines, and consumer health provides multiple revenue streams to back the dividend.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, Sanofi's roughly 4% yield is competitive but not the highest available. For context, peers such as PFE (Pfizer) have at times offered yields above 5%, while JNJ (Johnson & Johnson) and NVS (Novartis) typically yield closer to 3%. Sanofi's payout sits comfortably in the middle-to-upper range of this group.

Notably, Sanofi's payout ratio of roughly 37% is lower than that of several high-yield pharma peers, suggesting the dividend has more room to grow over time. For income-oriented investors, this balance of a solid current yield with a modest payout ratio makes Sanofi an appealing middle ground between maximum income and dividend growth potential.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and exchange-traded funds (ETFs) using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research and uncover income opportunities that match your criteria.

Is This Stock Attractive for Dividend Investors?

Sanofi may appeal to several types of dividend investors. Income-focused investors could value its near-4% yield, which is meaningful relative to many large-cap peers. Long-term dividend growth investors may appreciate the company's track record of consistent annual increases and its relatively low payout ratio, which leaves headroom for future raises. Conservative investors might be drawn to the defensive nature of the healthcare sector and Sanofi's diversified revenue base.

At the same time, the once-per-year payment schedule may be less convenient for investors who prefer a steady stream of quarterly or monthly income. Currency exposure also means U.S. holders of the ADR should expect some variability in the exact dollar amount received. Overall, Sanofi presents a balanced profile: a competitive yield, a conservative payout, and a stable business, though its annual distribution rhythm and currency sensitivity are factors dividend investors should weigh alongside their own income needs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations